Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Profit After Tax (2019 - 2025)

Benitec Biopharma has reported Profit After Tax over the past 7 years, most recently at -$11.8 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$11.8 million for Q4 2025, down 60.89% from a year ago — trailing twelve months through Dec 2025 was -$39.0 million (down 81.93% YoY), and the annual figure for FY2025 was -$37.9 million, down 74.24%.
  • Profit After Tax reached -$11.8 million in Q4 2025 per BNTC's latest filing, down from -$9.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$3.3 million in Q1 2022 and bottomed at -$11.8 million in Q4 2025.
  • Median Profit After Tax over the past 5 years was -$5.1 million (2022), compared with a mean of -$5.9 million.
  • The largest annual shift saw Profit After Tax grew 16.22% in 2022 before it crashed 118.6% in 2025.
  • Over 5 years, Profit After Tax stood at -$4.8 million in 2021, then decreased by 12.24% to -$5.4 million in 2022, then dropped by 25.63% to -$6.8 million in 2023, then decreased by 8.22% to -$7.4 million in 2024, then plummeted by 60.89% to -$11.8 million in 2025.
  • Business Quant data shows Profit After Tax for BNTC at -$11.8 million in Q4 2025, -$9.0 million in Q3 2025, and -$8.8 million in Q2 2025.